November 2021
Pharmaxis raising $9.2 million via Morgans
Pharmaxis is tapping investors to raise $9.2 million, with the capital set to support the next phase of clinical trials for its cancer and scar treatment candidates.
- Anthony Macdonald, Yolanda Redrup and Kanika Sood
September 2015
Pharmaxis has a new business model – is it now the least risky biotech stock?
In 2013 Pharmaxis looked set for the biotech graveyard, but after sacking 100 staff and signing three new deals, CEO Gary Phillips has refocused the company.
- Updated
- Jessica Gardner
July 2014
Pharmaxis shares plunge on Bronchitol funding threat
Pharmaxis has said a $US20 million payment from financier NovaQuest Capital Management is at risk following allegations that it has breached its contract, in a move that could be the killer blow for the embattled drug developer.
- Updated
- Jessica Gardner
April 2014
How to pick the next hot biotechnology stock
It’s a harsh but true assessment that many investors don’t understand biotechnology. So what hope is there for retail investors to profit from the next wonder drug?
- Updated
- Jessica Gardner
June 2013
2013 a tough year for small caps
The past 12 months have been a miserable affair for many small caps, with the index now trading at its lowest point since April 2009.
- Updated
- Sally Rose
May 2013
Stocks to watch on the ASX at close on Tuesday
Stocks to watch on the ASX at close on Tuesday: Bank of Queensland, Cabcharge Australia, New Hope Corporation, OZ Minerals, Pharmaxis, Suncorp Group, Virgin Australia Holdings
- Updated
January 2013
- Opinion
- Opinion
Deutsche cuts Pharmaxis to ‘sell’
Pharmaxis had a horror day yesterday with its share price nearly halving in value after it said the panel advising the US FDA gave its drug Bronchitol a negative recommendation.
- Updated
- Sarah Thompson and Anthony Macdonald
January 2013
Stocks to watch at noon on Tuesday
Stocks to watch on the Australian stock exchange at noon on Tuesday are Beach Energy, Lend Lease, Oil Search, Pharmaxis, Suncorp and Sydney Airport.
Pharmaxis in trading halt ahead of FDA review
Shares in biotech Pharmaxis have been placed in a two-day trading halt ahead of the decision by the expert advisory panel to the US FDA on whether to accept its Bronchitol drug.
- Updated
- Carrie LaFrenz
Pharmaxis braces for US review of new drug
Pharmaxis chief executive Alan Robertson says he has an anxious few weeks ahead as the company waits to find out the US Food and Drug Administration advisory committee recommendations on its Bronchitol drug.
- Updated
- Carrie LaFrenz
October 2012
Predator eyes Pharmaxis
Specialty pharmaceutical company Pharmaxis was the subject of takeover speculation over the weekend.
- Updated
- Sarah Thompson and Anthony Macdonald
July 2012
Pharmaxis feels better with homegrown model
When Julia Gillard addressed the Medicines Australia annual dinner in the Great Hall at Parliament House in February, she was determined to make her audience feel good.
- Updated
- Emma Connors
July 2012
Pharmaxis breathes a little easier
Phamaxis chief executive Alan Robertson says he might find time to give himself a small pat on the back on Wednesday, when the company’s flagship drug will finally get reimbursed by the Australian government.
- Updated
- Emma Connors
March 2012
Company briefs
Mineral Resources founder and executive director Chris Ellison has sold 3.4 million shares for $41.4 million, continuing a run of recent share sales by directors of the mining and mining services company.
- Updated
February 2012
Biotechs making a steady recovery
There is likely to be a sharp pick-up in interest in Australian biotechs this year as they move into their next phase of growth, which will pave the way for them to be taken over by global drug companies.
- Updated
- Brendon Lau
Crunch time for fallen hopefuls
The reporting season hasn’t quite kicked off but a number of juniors have already left a bad taste in investors’ mouths with experts expecting more negative than positive earnings surprises over the next four weeks.
- Updated
- Brendon Lau
January 2012
Company Briefs
Oil Search is within weeks of starting a drilling campaign that will determine the viability of expanding its $US15.7 billion Papua New Guinea liquefied natural gas project.
December 2011
Company briefs
Myer chief executive Bernie Brookes has sold a further 163,000 ordinary shares in the retailer, raising $368,250 towards the cost of building a house.
Hat’s out for venture capital funding
Australia’s venture capital industry received a much-needed $100 million commitment from the federal government on Wednesday, but it has done little to allay concerns about the commercialisation of future Australian ideas and innovation.
- Updated
- Anthony Macdonald
November 2011
- Opinion
- Opinion
Pharmaxis to raise $80m
Drug developer Pharmaxis plans to raise $80.2 million in a 1-for-3 accelerated pro-rata non-renounceable entitlement offer.
- Updated
- Sarah Thompson and Stephen Shore
